These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 14730104
1. Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. Zieba R, Wagrowska-Danilewicz M. Pol J Pharmacol; 2003; 55(6):1079-87. PubMed ID: 14730104 [Abstract] [Full Text] [Related]
4. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ. Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833 [Abstract] [Full Text] [Related]
5. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. Saad SY, Najjar TA, Alashari M. J Biochem Mol Toxicol; 2004 Nov; 18(2):78-86. PubMed ID: 15122649 [Abstract] [Full Text] [Related]
9. Influence of doxorubicin and carnosine on the standard 12-lead electrocardiogram in rabbits. Dzielska-Olczak M, Graczyk-Wojciechowska J, Pakulska W, Zieba R. Acta Pol Pharm; 2004 Dec; 61 Suppl():56-8. PubMed ID: 15909940 [Abstract] [Full Text] [Related]
10. Effects of indomethacin on hemodynamic parameters after intravenous administration of propranolol and enalaprilat in rabbits. Kasznicki J, Wiktorowska-Owczarek A. Pol J Pharmacol; 2001 Dec; 53(5):487-93. PubMed ID: 11990067 [Abstract] [Full Text] [Related]
11. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Imondi AR, Della Torre P, Mazué G, Sullivan TM, Robbins TL, Hagerman LM, Podestà A, Pinciroli G. Cancer Res; 1996 Sep 15; 56(18):4200-4. PubMed ID: 8797592 [Abstract] [Full Text] [Related]
15. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. Sterba M, Popelová O, Simunek T, Mazurová Y, Potácová A, Adamcová M, Kaiserová H, Ponka P, Gersl V. J Pharmacol Exp Ther; 2006 Dec 15; 319(3):1336-47. PubMed ID: 17003229 [Abstract] [Full Text] [Related]
19. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. Mohamed HE, Asker ME, Ali SI, el-Fattah TM. J Pharm Pharmacol; 2004 Jun 15; 56(6):757-68. PubMed ID: 15231041 [Abstract] [Full Text] [Related]